Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 98 of 116

  1. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  2. KO-MEN-008

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  3. KPT-330

    Karyopharm Therapeutics Inc

    Relapsed Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule active

    1 trial

  4. KPT-330

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. KPT-330

    Karyopharm Therapeutics Inc

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  6. KPT-9274

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  7. KPT-9274

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  8. KRAS Vaccine with Poly-ICLC adjuvant

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  9. KSH01 injection

    TScan Therapeutics

    Solid Tumor

    phase 1 small molecule active

    1 trial

  10. KSV01 Injection

    TScan Therapeutics

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  11. KT-333

    Kymera Therapeutics

    Non Hodgkin Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  12. KT-413

    Kymera Therapeutics

    Non Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  13. KT-US-499-0150

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  14. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  15. KXV01 TCR Lentinvivo Injection

    TScan Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    2 trials

  16. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  17. LB-100 for Injection

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Tumors

    phase 1 small molecule completed

    1 trial

  18. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  19. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  20. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  21. LCAR-AIO Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  22. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  23. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  24. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  25. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  26. LCAR-G08 cells

    Nanjing Legend Biotech Co.

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  27. LCAR-HL30 cells

    Nanjing Legend Biotech Co.

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  28. LCAR-M23 cells

    Nanjing Legend Biotech Co.

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

  29. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  30. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  31. LENVIMA hard capsules for Advanced Renal Cell Carcinoma

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  32. LN-144

    Iovance Biotherapeutics B.V.

    Stage IIIB Melanoma

    phase 1 mab terminated

    1 trial

  33. LN-145/LN-144

    Iovance Biotherapeutics B.V.

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  34. LOXO-ENC-23001

    Eli Lilly Co.

    Advanced/metastatic solid tumor

    phase 1 other active

    1 trial

  35. LOXO-FRA-24001

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  36. LOXO-LNC-24001

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  37. LOXO-PIK-21001

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  38. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  39. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  40. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  41. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  42. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  43. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  44. LY3484356

    Eli Lilly and Company

    Breast Neoplasms

    phase 1 small molecule active

    1 trial

  45. Larotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 1 small molecule active

    1 trial

  46. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  47. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  48. Letrozole

    Context Therapeutics

    Metastatic Breast Cancer

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.